Comparative Pharmacology
Head-to-head clinical analysis: EXELON versus PYRIDOSTIGMINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXELON versus PYRIDOSTIGMINE BROMIDE.
EXELON vs PYRIDOSTIGMINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exelon (rivastigmine) is a reversible, non-competitive acetylcholinesterase and butyrylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
Reversible acetylcholinesterase inhibitor, prolonging the action of acetylcholine at nicotinic and muscarinic receptors.
Initial: 1.5 mg orally twice daily; after 2 weeks increase to 3 mg twice daily; then after 2 weeks increase to 4.5 mg twice daily; then after 2 weeks increase to 6 mg twice daily (maximum). For transdermal patch: initial 4.6 mg/24 hr applied once daily; after 4 weeks increase to 9.5 mg/24 hr; may increase to 13.3 mg/24 hr after additional 4 weeks.
Oral: 60-120 mg every 3-4 hours (max 360 mg/day). Intravenous: 0.1-0.25 mg/kg IV (max 10 mg per dose) for reversal of nondepolarizing neuromuscular blockade, given with glycopyrrolate or atropine. Intramuscular: 0.2-1 mg for postoperative urinary retention.
None Documented
None Documented
Terminal half-life: ~1.5 hours; clinical context: tid dosing recommended due to rapid elimination.
Terminal half-life: 1-2 hours (prolonged in renal impairment; up to 6 hours in anuria)
Renal (97%) with unchanged drug <1%; biliary/fecal as metabolites.
Renal: 70-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor